LinkOPH

MIAMI — Phase 3 studies of lampalizumab are underway based on results of the phase 2 MAHALO study, which showed evidence that treatment slows the rate of geographic atrophy progression in patients with age-related macular degeneration, a speaker told colleagues.“Certainly there is a significant unmet medical need with regard to geographic atrophy,” Carl D. Regillo, MD, said at Angiogenesis, Exudation, and Degeneration 2015. “There’s more than 5 million people worldwide affected by GA, and there’s no effective treatment.”

Read more →

MIAMI — Vision in dim light improves twice as much as vision in normal light with Lucentis therapy in patients with age-related macular degeneration, Ronald E. Frenkel, MD, FACS, told colleagues at Angiogenesis, Exudation, and Degeneration 2015.“The gap between normal and dim vision at baseline may predict the patient’s response to treatment,” Frenkel said. “A smaller gap may be a manifestation of more mild retinal disease, and a wider gap portends poor vision gains.”

Read more →

SAN FRANCISCO — Moving glaucoma innovation to focus on early treatment will save money and improve patient quality of life, according to the keynote speaker at the Glaucoma Research Foundation’s Glaucoma 360 New Horizons Forum here. Paul P. Lee, MD, JD, gave the Drs. Henry and Frederick Sutro Memorial Lecture on transcendental goals for innovation in eye health.

Read more →

Today, so-called conventional corneal collagen cross-linking has become the gold standard to halt the course of progressive keratoconus. In this photoreticulation technique, the collagen fibers are bonded with the surrounding corneal matrix. Chemical t…

Read more →